

The Latest Advancement in remedē[®] System Technology is now MRI compatible

The remedē System is now approved for Magnetic Resonance Imaging (MRI) compatibility under specific conditions.

This new indication makes it available to patients who have a regular need for MRI imaging or may be concerned about requiring an MRI in the future.



Compatibility chart

remedē IPG	Model 1001	Model 1100	Model 1600
Conditional MRI compatibility	YES	YES	YES

For a complete list of MR compatible accessories, please access our online [MRI manual](#).

MRI scanning conditions

Static Magnetic Field Strength (B_0)	1.5T and 3T
MR Scanner Type	Cylindrical
B_0 Field Orientation	Horizontal
Maximum Spatial Field Gradient	19.1 T/m (1910 gauss/cm)
Maximum Gradient Slew Rate	200 T/m/s per axis
RF Excitation	Circularly Polarized (CP)
RF Transmit Coil Type	Integrated Whole Body Transmit Coil, Head Coil
Operating Mode	
RF Conditions	See tables below
Scan Duration & Zones	


Image Artifact

The presence of the **remedē** Implant System may produce an image artifact of 7.8 cm at the IPG and 1.4 cm at the distal end of the lead. Some manipulation of scan parameters may be needed to compensate for the artifact

Scan the QR code to read all our instructions and recommendations for MRI use



Recommendations for scan durations, zones, and coil positioning restrictions



Field Strength	Zone	Normal Operating Mode*		Whole Body SAR Level: 1 W/kg		Whole Body SAR Level: 0.5 W/kg	
		Active Scan Time (minutes)	Wait Time (minutes)	Active Scan Time (minutes)	Wait Time (minutes)	Active Scan Time (minutes)	Wait Time (minutes)
1.5 T	Head & Neck	4	12	8.5	12	17	12
	Torso	4	12	8.5	12	17	12
	Hips & Thighs	Active RF Scan Time is 60 minutes in a 75-minute time period.					
	Lower Legs						
3 T	Head & Neck	2	12	4.5	12	9.5	12
	Torso	2	12	6	12	12	12
	Hips & Thighs	15	N/A**	Active RF Scan Time is 60 minutes in a 75-minute time period.			
	Lower Legs						

* SAR limits of Normal Operating Mode as defined in IEC 60601-2-33:2022 (ED 4.0) (Table 201.104): Whole Body SAR: 2 W/kg, Head SAR: 3.2 W/kg, Partial Body SAR: 2-10 W/kg.

** The wait time is not applicable since consecutive 3T scans are not permitted in the Hips & Thighs

Important Note

Prior to the MRI scan, the **remedē** System needs to be checked and turned OFF. Please refer to the MRI manual for detailed information.

Important Safety Information

The **remedē** System is indicated for moderate to severe Central Sleep Apnea (CSA) in adult patients. A doctor will need to evaluate the patient's condition to determine if the **remedē** System is appropriate. The **remedē** System should not be implanted during an active infection and patients will not be able to have diathermy (special heat therapies). The device is MR Conditional. The conditions and precautions can be found in the **remedē** System MRI guidelines manual. The **remedē** System may be used with another stimulation device such as a heart pacemaker or defibrillator; special testing will be needed to ensure the devices are not interacting. As with any surgically implanted device, there are risks related to the surgical procedure itself which may include, but are not limited to, pain, swelling, and infection. Once the therapy is turned on, some patients may experience discomfort from stimulation and/or from the presence of the device. The majority of these events are resolved either on their own or by adjusting the therapy settings. The **remedē** System may not work for everyone. There are additional risks associated with removing the system. If it is decided to remove the system, another surgery will be required. Be sure to understand all the risks and benefits associated with the implantation of the **remedē** System. For further information please visit remede.zoll.com, call 952-540-4470 or email info@remede.zoll.com. **Contraindications:** The **remedē** System is contraindicated for use in patients with an active infection. See the Instructions for Use for complete information regarding the procedure, indications for use, contraindications, warnings, precautions, and potential adverse events.

Rx Only.

The **remedē** System, **remedē** EL System, and **remedē** EL-X System have received FDA approval. The **remedē** System model 1001 has received CE Mark approval.

ZOLL MEDICAL CORPORATION

12400 Whitewater Dr., Suite 150 | Minnetonka, MN 55343 | 952-540-4470 | info@remede.zoll.com | remede.zoll.com

Copyright © 2023 ZOLL Medical Corporation. All rights reserved. Respicardia and **remedē** are registered trademarks of ZOLL Respicardia, Inc. in the United States and/or other countries. ZOLL is a registered trademark of ZOLL Medical Corporation in the United States and/or other countries.

Printed in the U.S.A.
MKT 2981, Rev A

For subsidiary addresses and fax numbers, as well as other global locations, please go to www.zoll.com/contacts.

ZOLL®